Stock Financial Ratios

HTGM / HTG Molecular Diagnostics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.78
Volume2,765,800.00
Market Cap ($M)63.29
Enterprise Value ($M)-1.31
Book Value ($M)-5.59
Book Value / Share-0.69
Price / Book-14.01
NCAV ($M)-8.91
NCAV / Share1.19
Price / NCAV-7.69
Income Statement (mra) ($M)
Revenue5.13
EBITDA-24.33
Net Income-26.04
Balance Sheet (mrq) ($M)
Cash & Equivalents9.05
Cash / Share1.12
Assets0.00
Liabilities21.76
Quick Ratio1.36
Current Ratio1.51
Management Effectiveness (mra)
Return on Invested Capital (ROIC)4.66
Return on Assets (ROA)-1.41
Return on Equity (ROE)4.66
Identifiers and Descriptors
CUSIP40434H104
Central Index Key (CIK)1169987
Industry Groups
SIC 3826 - Laboratory Analytical Instruments
Share Statistics
Common Stock Shares Outstanding7,938,571
Common Shares Outstanding8,052,451
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Cash And Equivalents Per Share1.12
Equity Per Share0.00
Liabilities Per Share2.70
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.16
Accounts Receivable Per Share0.39
Retained Earnings Per Share0.00
Cash Per Share1.12
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Treasury Stock Per Share0.00
Liabilities Current Per Share0.00
Debt Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Assets Current Per Share1.74

HTGM : HTG Molecular Diagnostics Stock Analysis and Research Report

HTG Molecular is a commercial stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. Molecular profiling is the collection of information about multiple molecular targets, such as DNA and RNA, also called biomarkers, in a biological sample. Molecular profiling information has many important applications, from basic research to molecular diagnostics in personalized medicine. Its technology can be used throughout that range of applications, which is just one of its many benefits. Its focus is on clinical applications. Its primary customer segments include biopharmaceutical companies, academic research centers and molecular testing laboratories.

Historically, molecular profiling has faced several technical challenges in clinical applications. These include (i) limited “multiplexing,” which means only a few biomarkers could be tested in a single sample; (ii) the need for vast amount...

Click for full article

Related News Stories

HTG Molecular: Upside For This ~$3.50 'Busted IPO'?

2018-01-11 seekingalpha
This 'Busted IPO' has started to garner positive analyst support, has some recent insider buying and a compelling technology platform. (29-5)

Biotech Forum Daily Digest For Jan. 8th

2018-01-08 seekingalpha
The biotech sector had a solid start to 2018, as did the overall market. The sector is selling off to start this week, however. (356-3)

BRIEF-HTG Molecular, Illumina Agreed To Third Development Plan Under Parties' Amended & Restated Development & Supply Agreement

2017-12-27 reuters
* HTG MOLECULAR DIAGNOSTICS - ON DEC 23, CO, ILLUMINA AGREED TO THIRD DEVELOPMENT PLAN UNDER PARTIES’ AMENDED & RESTATED DEVELOPMENT & SUPPLY AGREEMENT (29-3)

BRIEF-HTG Molecular Diagnostics And Unit Of QIAGEN Amended First Statement Of Work Under Master Agreement

2017-12-20 reuters
* HTG MOLECULAR DIAGNOSTICS - ON DEC. 18. CO, UNIT OF QIAGEN, AMENDED FIRST STATEMENT OF WORK UNDER MASTER AGREEMENT - SEC FILING (29-2)

Your Daily Pharma Scoop: Portola Upside, Novartis Reports Positive Cosentyx Data, Keryx Tumbles

2017-11-09 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (482-6)

CUSIP: 40434H104